(Q38121762)

29 August 2017

title

Therapeutic effects of thalidomide in hematologic disorders: a review (English)

1 reference

29 August 2017

0 references

Miao Xu

1

1 reference

29 August 2017

Yu Hou

series ordinal

2

1 reference

29 August 2017

Lei Sheng

series ordinal

3

1 reference

29 August 2017

Jun Peng

series ordinal

4

1 reference

29 August 2017

publication date

15 July 2013

1 reference

29 August 2017

published in

Frontiers of medicine

1 reference

29 August 2017

volume

7

1 reference

29 August 2017

issue

3

1 reference

29 August 2017

page(s)

290-300

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

29 August 2017

1 reference

The treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Bone marrow angiogenesis and progression in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Current therapeutic strategy for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Molecular mechanisms of novel therapeutic approaches for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Pharmacological properties of thalidomide and its analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Thalidomide down-regulates transcript levels of GC-rich promoter genes in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Thalidomide and hematopoietic-cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Advances in therapy of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Update on therapeutic options in Waldenström macroglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Treatment of Waldenstrom's Macroglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Waldenström macroglobulinemia: 2012 update on diagnosis, risk stratification, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Thalidomide and rituximab in Waldenstrom macroglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Guidelines on the management of Waldenström macroglobulinaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Successful treatment with rituximab and thalidomide of POEMS syndrome associated with Waldenstrom macroglobulinemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Standard therapy of advanced Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Thalidomide and lenalidomide: Mechanism-based potential drug combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Thalidomide therapy induces response in relapsed mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Thalidomide for the treatment of patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Thalidomide treatment reduces apoptosis levels in bone marrow cells from patients with myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Combination of erythropoietin and thalidomide for the treatment of anemia in patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: a clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Novel treatments for epistaxis in hereditary hemorrhagic telangiectasia: a systematic review of the clinical experience with thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Teratogenic effects of thalidomide: molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Mechanism of action in thalidomide teratogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Adverse effects of thalidomide administration in patients with neoplastic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Thalidomide therapy and deep venous thrombosis in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Phase II trial of thalidomide in renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Thalidomide, deep venous thrombosis and vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Peripheral nervous system involvement in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Thalidomide: A review of approved and investigational uses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Thalidomide and lenalidomide in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Thalidomide-induced neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Chemotherapy-induced neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Thalidomide-induced neuropathy: a ganglionopathy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Thalidomide neurotoxicity: prospective study in patients with lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Thalidomide neuropathy in patients treated for metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Isolated thrombocytopenia induced by thalidomide in a patient with multiple myeloma: case report and review of literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Thalidomide-associated thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Toxic epidermal necrolysis following thalidomide and dexamethasone treatment for multiple myeloma: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0277-Z

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma

21 January 2018

1 reference

12 December 2020

Bone marrow of patients with active multiple myeloma: angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44

1 reference

12 December 2020

1 reference

12 December 2020

Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.

1 reference

12 December 2020

Thalidomide in the management of chronic graft-versus-host disease in children following bone marrow transplantation

1 reference

12 December 2020

Using thalidomide in a patient with epithelioid leiomyosarcoma and Osler-Weber-Rendu disease.

1 reference

12 December 2020

Thalidomide for treatment of graft-versus-host disease

1 reference

12 December 2020

Advances in biology and therapy of multiple myeloma.

1 reference

12 December 2020

Thalidomide for the treatment of myelodysplastic syndrome in Taiwan: results of a phase II trial.

1 reference

12 December 2020

Economic issues in lung cancer: a review

1 reference

12 December 2020

Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma

1 reference

12 December 2020

Hereditary hemorrhagic telangiectasia/avastin

1 reference

12 December 2020

Successful treatment with thalidomide of acute graft-versus-host disease after bone-marrow transplantation

1 reference

12 December 2020

Pathogenesis, etiology and epidemiology of myelodysplastic syndromes

1 reference

12 December 2020

Is thalidomide effective for the treatment of gastrointestinal bleeding in hereditary hemorrhagic telangiectasia?

1 reference

12 December 2020

The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis

1 reference

12 December 2020

First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma.

1 reference

12 December 2020

Treatment and prevention of acute graft-versus-host disease with thalidomide in a rat model

1 reference

12 December 2020

Hereditary hemorrhagic telangiectasia: diagnosis and management

1 reference

12 December 2020

Management of thalidomide toxicity

1 reference

12 December 2020

Thalidomide treatment for chronic graft-versus-host disease

1 reference

12 December 2020

Proposals for the classification of the myelodysplastic syndromes

1 reference

12 December 2020

Polyneuropathy after neurosedyn (thalidomide) and its prognosis

1 reference

12 December 2020

Thalidomide induced remission of refractory diffuse large B-Cell Lymphoma post-allogeneic SCT

1 reference

12 December 2020

Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis

1 reference

12 December 2020

Response to thalidomide therapy in refractory chronic graft-versus-host disease

1 reference

12 December 2020

Successful treatment of refractory angioimmunoblastic T-cell lymphoma with thalidomide and dexamethasone

1 reference

12 December 2020

Thalidomide for treatment of patients with chronic graft-versus-host disease.

1 reference

12 December 2020

Epidemiology of myelodysplastic syndromes: many questions remain

1 reference

12 December 2020

10.1007/S11684-013-0277-Z

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

1024535281

0 references

1 reference